JMJD6 and esophageal squamous cell carcinoma: Furthermore, our results also indicated that the prognosis of ESCC patients with high JMJD6 expression was poor in the late clinical stage (stage III) (HR = 2.306 [1.366–3.894], Logrank p = 0.002).